Efficacy of treatments for patients with obsessive‐compulsive disorder: A systematic review

Purpose: This systematic review examines the efficacy of pharmacological therapy for obsessive‐compulsive disorder (OCD), addressing two major issues: which treatment is most effective in treating the patient's symptoms and which is beneficial for maintaining remission. Data sources: Seven databases were used to acquire articles. The key words used to search for the relative topics published from 1996 to 2007 were “obsessive‐compulsive disorder” and “Yale‐Brown obsession‐compulsion scale.” Based on the inclusion and exclusion criteria, 25 studies were selected from 57 potentially relevant studies. Conclusions: The effects of treatment with clomipramine and selective serotonin reuptake inhibitors (SSRIs: fluvoxamine, sertraline, fluoxetine, citalopram, and escitalopram) proved to be similar, except for the lower adherence rate in case of clomipramine because of its side effects. An adequate drug trial involves administering an effective daily dose for a minimum of 8 weeks. An augmentation strategy proven effective for individuals refractory to monotherapy with SSRI treatment alone is the use of atypical antipsychotics (risperidone, olanzapine, and quetiapine). Implications for practice: Administration of fluvoxamine or sertraline to patients for an adequate duration is recommended as the first‐line prescription for OCD, and augmentation therapy with risperidone, olanzapine, or quetiapine is recommended for refractory OCD.

[1]  Leonardo Franklin Fontenelle,et al.  The analytical epidemiology of obsessive–compulsive disorder: Risk factors and correlates , 2008, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[2]  D. Stein,et al.  Escitalopram prevents relapse of obsessive-compulsive disorder , 2007, European Neuropsychopharmacology.

[3]  H. Westenberg,et al.  Effects of quetiapine on cognitive functioning in obsessive–compulsive disorder , 2007, International clinical psychopharmacology.

[4]  Quetiapine Addition in Obsessive-Compulsive Disorder: Is Treatment Outcome Affected by Type and Dose of Serotonin Reuptake Inhibitors? , 2007, Biological Psychiatry.

[5]  Wade Junek,et al.  Essential Psychopharmacology: The Prescriber’s Guide , 2006 .

[6]  U. Müller,et al.  Serotonin Transporter Imaging with [123I]β-CIT SPECT before and after One Year of Citalopram Treatment of Obsessive-Compulsive Disorder , 2006, Neuropsychobiology.

[7]  E. Storch,et al.  The children's Yale-Brown obsessive-compulsive scale: psychometric properties of child- and parent-report formats. , 2006, Journal of anxiety disorders.

[8]  A. Harden,et al.  Methodological Issues in Combining Diverse Study Types in Systematic Reviews , 2005 .

[9]  B. Dell’Osso,et al.  Augmentation strategy with olanzapine in resistant obsessive compulsive disorder: an Italian long-term open-label study , 2005, Journal of psychopharmacology.

[10]  N. Fineberg,et al.  Adding quetiapine to SRI in treatment-resistant obsessive–compulsive disorder: a randomized controlled treatment study , 2005, International clinical psychopharmacology.

[11]  G. Andrews,et al.  The changing prevalence and severity of obsessive-compulsive disorder criteria from DSM-III to DSM-IV. , 2005, The American journal of psychiatry.

[12]  L. Bellodi,et al.  Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder: a double-blind, placebo-controlled study , 2005, European Neuropsychopharmacology.

[13]  Dan J Stein,et al.  Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind, randomised, placebo-controlled study [ISRCTN83050762] , 2005, BMC psychiatry.

[14]  R. Tabrizchi.  Essential Psychopharmacology: The Prescriber's Guide , 2005 .

[15]  P. Thomsen.  Risperidone augmentation in the treatment of severe adolescent OCD in SSRI-refractory cases: a case-series. , 2004, Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists.

[16]  H. Westenberg,et al.  A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors. , 2004, The Journal of clinical psychiatry.

[17]  J. Davidson,et al.  A double-blind combination study of clonazepam with sertraline in obsessive-compulsive disorder. , 2004, Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists.

[18]  A. Yazıcı,et al.  Amisulpiride augmentation in treatment resistant obsessive–compulsive disorder: an open trial , 2003, Human psychopharmacology.

[19]  E. Hollander,et al.  A double-blind, placebo-controlled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive-compulsive disorder. , 2003, The Journal of clinical psychiatry.

[20]  A. E. Rosa,et al.  Olanzapine augmentation of paroxetine-refractory obsessive-compulsive disorder , 2003, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[21]  John Piacentini,et al.  Fluoxetine in children and adolescents with OCD: a placebo-controlled trial. , 2002, Journal of the American Academy of Child and Adolescent Psychiatry.

[22]  M. Atmaca,et al.  Quetiapine augmentation in patients with treatment resistant obsessive–compulsive disorder: a single-blind, placebo-controlled study , 2002, International clinical psychopharmacology.

[23]  R. Swinson,et al.  Sertraline and Fluoxetine Treatment of Obsessive-Compulsive Disorder: Results of a Double-Blind, 6-Month Treatment Study , 2002, Journal of clinical psychopharmacology.

[24]  D. Robinson,et al.  Efficacy of sertraline in the long-term treatment of obsessive-compulsive disorder. , 2002, The American journal of psychiatry.

[25]  E. Mundo,et al.  Fluvoxamine in obsessive‐compulsive disorder: similar efficacy but superior tolerability in comparison with clomipramine , 2001, Human psychopharmacology.

[26]  J. Daléry,et al.  Consensus on the Practical Use of Amisulpride, an Atypical Antipsychotic, in the Treatment of Schizophrenia , 2001, Neuropsychobiology.

[27]  S. Bellino,et al.  Olanzapine augmentation of fluvoxamine-refractory obsessive–compulsive disorder (OCD): a 12-week open trial , 2000, Psychiatry Research.

[28]  C. McDougle,et al.  A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. , 2000, Archives of general psychiatry.

[29]  C. Berlin.  Sertraline in Children and Adolescents with Obsessive-Compulsive Disorder , 1999 .

[30]  E. Cook,et al.  Sertraline in children and adolescents with obsessive-compulsive disorder: a multicenter randomized controlled trial. , 1998, JAMA.

[31]  E. Hollander,et al.  SSRIs in the Treatment of obsessive‐compulsive disorder , 1998, Depression and anxiety.

[32]  J. Bisserbe,et al.  A double-blind comparison of sertraline and clomipramine in outpatients with obsessive-compulsive disorder , 1997, European Psychiatry.

[33]  J. Cottraux,et al.  Double-blind comparison of fluoxetine versus clomipramine in the treatment of obsessive compulsive disorder , 1996, European Neuropsychopharmacology.

[34]  E. Hollander,et al.  Fluvoxamine versus clomipramine for obsessive-compulsive disorder: a double-blind comparison. , 1996, Journal of clinical psychopharmacology.

[35]  A R Jadad,et al.  Assessing the quality of reports of randomized clinical trials: is blinding necessary? , 1996, Controlled clinical trials.

[36]  E. Hollander,et al.  Comparison of clomipramine, alprazolam and placebo in the treatment of obsessive—compulsive disorder , 1992 .